Across TCGA pan-cancer cohorts, SAPCD2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SAPCD2 data layer compared with 29 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher SAPCD2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SAPCD2 expression acts as an unfavorable survival marker.

CESC, SCLC, and COAD are the cancer types where SAPCD2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	DFS	Median	All	0.193	0.740	.010	12	view →
SCLC	OS	Median	All	0.082	0.708	<.001	12	view →
COAD	OS	Median	All	0.295	0.621	.042	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: SAPCD2 tumor-vs-normal RNA expression · all SAPCD2 data types